Drugs / Meropenem
Meropenem
also known as
MERREM I.V. · ICI 194,660 · Mepin · MEPM · Meronem · Meronem (meropenem) · Meropenem "Hospira" · Meropenem (as trihydrate) · +11 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Vaborem | — | 2018-11-20 | europa.eu ↗ |
| Label expansion | US (FDA) | MERREM IV | — | 2005-05-25 | fda.gov ↗ |
| Approved | US (FDA) | MERREM IV | — | 1996-06-21 | fda.gov ↗ |
Trials 80 · started per year
today
US approved 1996
EU approved 2018
1
3
2
2
2
1
2
4
5
5
5
1
2
7
4
3
2
7
3
3
4
8
4
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03950544 | Jan 2019 → Aug 2020 | bacterial infectious disease | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT01633762 | Apr 2012 → Apr 2013 | diabetes mellitus, obesity disorder, osteoporosis | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| Phase 111 trials | ||||||
| Phase 1 | NCT07124468 | Sep → Dec 2025 overdue | infectious disease | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06916156 | Apr → Aug 2025 | — | Antabio | Completed | No outcome recorded |
| Phase 1 | NCT06527677 | Jul 2024 → Jul 2025 | impaired renal function disease | Antabio | Completed | No outcome recorded |
| Phase 1 | NCT05905913 | Apr 2023 → Jan 2024 | — | Antabio | Completed | No outcome recorded |
| Phase 1 | NCT05226923 | Jan → Oct 2022 | bacterial infectious disease | Sumitovant Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04816968 | Sep 2021 → Sep 2023 | bacterial infectious disease | Ospedale San Carlo Borromeo | Unknown | No outcome recorded |
| Phase 1 | NCT05058105 | Oct 2020 → Feb 2021 | — | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03564158 | May → Nov 2018 | — | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03174795 | Jul → Dec 2017 | urinary tract infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03182504 | Jun → Aug 2017 | gram-negative bacterial infections | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02972255 | Oct 2016 → Mar 2017 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01554124 | Feb 2013 → Dec 2014 | bacterial meningitis | PENTA Foundation | Completed | No outcome recorded |
| Phase 1/2 | NCT02212392 | Jan → Dec 2013 | acute pancreatitis | Benazir Bhutto Hospital, Rawalpindi | Completed | No outcome recorded |
| Phase 1/2 | NCT00621192 | Jun 2008 → Oct 2009 | necrotizing enterocolitis, peritonitis | The Emmes Company, LLC | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT07524920 | Apr → Aug 2026 overdue | bacterial infectious disease | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06828848 | Feb 2025 → Oct 2027 expected | gram-negative bacterial infections | Menarini Group | Recruiting | No outcome recorded |
| Phase 2 | NCT05060419 | Oct 2021 → Apr 2022 | acute pyelonephritis | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04629378 | Aug 2020 → Jun 2021 | tuberculosis | TASK Applied Science | Completed | No outcome recorded |
| Phase 2 | NCT05896930 | Nov 2017 → Jan 2021 | pulmonary tuberculosis | TASK Applied Science | Completed | No outcome recorded |
| Phase 2 | NCT03174184 | Aug 2017 → May 2022 | pulmonary tuberculosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT02349841 | Sep → Dec 2014 | pulmonary tuberculosis | TASK Applied Science | Completed | No outcome recorded |
| Phase 2 | NCT01570192 | Sep 2010 → Apr 2015 | bacterial pneumonia | University of Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00438269 | Feb 2003 → Mar 2005 | nosocomial infection, pneumonia | Canadian Critical Care Trials Group | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT07113574 | Aug 2021 → Jul 2022 | chronic renal failure syndrome, infectious peritonitis | Karl Landsteiner Insitute for Nephrology and Haemato-Oncology | Completed | No outcome recorded |
| Phase 2/3 | NCT04876430 | May 2021 → Mar 2022 | bacterial infectious disease | Hospital de Clinicas de Porto Alegre | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT07113587 | Apr 2014 → Jul 2017 | infectious peritonitis | Karl Landsteiner Insitute for Nephrology and Haemato-Oncology | Completed | No outcome recorded |
| Phase 2/3 | NCT01455246 | Oct 2010 → Apr 2014 | cirrhosis of liver | University of Padova | Terminated | No outcome recorded |
| Phase 313 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT07327619 | Jan 2026 → Jun 2028 expected | bacterial pneumonia | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07089186 | Apr 2025 → Dec 2026 expected | bacterial pneumonia, urinary tract infection | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06633718 | Oct 2024 → May 2027 expected | infectious peritonitis | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05392634 | Feb 2022 → Feb 2023 | urinary bladder cancer | N.N. Petrov National Medical Research Center of Oncology | Unknown | Met primary |
| Phase 3 | NCT06739382 | Jan → Dec 2021 | ventilation pneumonitis | Beni-Suef University | Completed | No outcome recorded |
| Phase 3 | NCT03006679 | Aug 2018 → Jun 2020 | bacterial pneumonia | Melinta Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02166476 | Nov 2014 → Apr 2016 | acute pyelonephritis | Melinta Therapeutics, Inc. | Completed | Met primary |
| Phase 3 | NCT01970371 | Sep 2014 → Aug 2016 | acute pyelonephritis, bacterial pneumonia | Achaogen, Inc. | Completed | Missed primary |
| Phase 3 | NCT01551394 | Sep 2012 → Dec 2014 | infectious disease with sepsis | PENTA Foundation | Completed | No outcome recorded |
| Phase 3 | NCT01110382 | Dec 2010 → Sep 2013 | abscess, appendicitis, ileus, intestinal perforation +1 | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00307099 | Oct 2006 → Feb 2007 | bacterial infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 3 | NCT00050401 | Jul 2002 → Sep 2004 | pneumonia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00619710 | Feb 2001 → Dec 2003 | abscess, cellulitis, skin infection | Pfizer | Completed | No outcome recorded |
| Phase 430 trials · 3 met primary · 2 missed | ||||||
| Phase 4 | NCT07484633 | Apr 2026 → Apr 2028 expected | infectious disease with sepsis | Semmelweis University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06929702 | Jul 2025 → Oct 2027 expected | — | University Hospital, Ghent | Recruiting | No outcome recorded |
| Phase 4 | NCT06184659 | Jun 2025 → Jun 2028 expected | infectious disease with sepsis | Scandinavian Critical Care Trials Group | Recruiting | No outcome recorded |
| Phase 4 | NCT07445282 | May → Nov 2025 | typhoid fever | Sheikh Zayed Medical College | Completed | No outcome recorded |
| Phase 4 | NCT06766461 | Jan 2025 → Dec 2026 expected | infectious disease with sepsis | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07122596 | Apr → Aug 2024 | infectious disease with sepsis, primary bacterial infectious disease | Pakistan Navy Station Shifa Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06293677 | Mar 2024 → Mar 2026 overdue | neutropenia | Centre Hospitalier Universitaire Vaudois | Recruiting | No outcome recorded |
| Phase 4 | NCT05862402 | May 2023 → May 2024 | Klebsiella pneumonia | Phramongkutklao College of Medicine and Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05427747 | Jan 2023 → Jan 2024 | infectious peritonitis | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT05393505 | Oct 2022 → Mar 2025 | neutropenia | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT04671589 | Jun 2021 → Jun 2022 | poisoning | Mabaret Al-Asafara Hospitals | Unknown | No outcome recorded |
| Phase 4 | NCT04154722 | Jun 2019 → Dec 2020 | typhoid fever | Ziauddin University | Completed | No outcome recorded |
| Phase 4 | NCT04233996 | Jun 2019 → Dec 2021 | neutropenia | Hospital Universitari de Bellvitge | Unknown | No outcome recorded |
| Phase 4 | NCT03452839 | Jun 2018 → Oct 2022 | infectious disease | Vita-Salute San Raffaele University | Completed | Missed primary |
| Phase 4 | NCT03645668 | Jan 2018 → Nov 2019 | infectious disease with sepsis | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03108690 | Oct 2017 → Mar 2023 | bacterial infectious disease | Sara Thønnings | Withdrawn | No outcome recorded |
| Phase 4 | NCT03237182 | Jun 2017 → Dec 2022 | multidrug-resistant tuberculosis | Centre for the AIDS Programme of Research in South Africa | Terminated | No outcome recorded |
| Phase 4 | NCT02463747 | Jun 2015 → Jun 2017 | neutropenia | Tel-Aviv Sourasky Medical Center | Unknown | Met primary |
| Phase 4 | NCT02149329 | Dec 2014 → Aug 2019 | hematopoietic and lymphoid cell neoplasm, neutropenia | Amsterdam UMC, location VUmc | Completed | Met primary |
| Phase 4 | NCT01944319 | Jul 2013 → Oct 2015 | respiratory tract infectious disorder | Qingtao Zhou | Completed | Met primary |
| Phase 4 | NCT01732250 | Mar 2013 → Jan 2017 | gram-negative bacterial infections | Mical Paul | Completed | Missed primary |
| Phase 4 | NCT02213796 | Jan → Dec 2013 | infectious disease with sepsis | Sutep Jaruratanasirikul | Completed | No outcome recorded |
| Phase 4 | NCT01992198 | Jul 2012 → Dec 2015 | acute necrotizing pancreatitis | Erzhen Chen | Unknown | No outcome recorded |
| Phase 4 | NCT01429259 | Feb 2012 → Jan 2014 | Pseudomonas aeruginosa infectious disease, cystic fibrosis, pneumonia | Joseph Kuti | Completed | No outcome recorded |
| Phase 4 | NCT02506686 | Sep 2008 → Dec 2009 | central nervous system infectious disorder | Huashan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00410527 | Aug 2006 → May 2007 | bacterial infectious disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 4 | NCT02615041 | Jan 2004 → Jan 2005 | — | Sutep Jaruratanasirikul | Completed | No outcome recorded |
| Phase 4 | NCT00061438 | Feb 2003 → Dec 2004 | acute necrotizing pancreatitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00318994 | Feb 2002 → Sep 2005 | pancreatitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00318552 | Jan 2002 → Jun 2006 | infectious disease with sepsis | Pfizer | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07641348 | Jul 2026 → Jan 2027 expected | typhoid fever | Iqra Asghar Ali | Not yet recruiting | No outcome recorded |
| — | NCT05578586 | Dec 2021 → Dec 2026 expected | — | Oslo University Hospital | Recruiting | No outcome recorded |
| — | NCT03157388 | Jun 2017 → Jun 2018 | alcoholic hepatitis | University of Aarhus | Completed | No outcome recorded |
| — | NCT02840136 | Feb 2016 → Sep 2017 | cystic fibrosis | University Ghent | Terminated | No outcome recorded |
| — | NCT01572558 | Feb → Oct 2012 | appendicitis | Karolinska University Hospital | Completed | No outcome recorded |
| — | NCT01158937 | May 2010 → Jan 2014 | cystic fibrosis | Unity Health Toronto | Terminated | No outcome recorded |
| — | NCT00579956 | Dec 2007 → Sep 2010 | melioidosis | University of Oxford | Unknown | No outcome recorded |
| — | NCT00153634 | Mar 2004 → Nov 2007 | chronic bronchitis, cystic fibrosis | Seattle Children's Hospital | Completed | No outcome recorded |
| Comparator or background therapy95 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06672276 Comparator | Nov 2024 → May 2025 | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05340530 Comparator | Apr 2022 → Dec 2023 | infectious disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT07096310 Comparator | Jan 2024 → Jan 2026 overdue | infectious disease with sepsis | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04555798 Comparator | Feb 2022 | respiratory failure | Mohamed Gaber Allam | Completed | No outcome recorded |
| Phase 1/2 | NCT04553367 Comparator | Jul 2020 → Dec 2021 | acute respiratory distress syndrome, infectious disease with sepsis | King Abdul Aziz Specialist Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT06072248 Comparator | Jul 2020 → Dec 2021 | acute respiratory distress syndrome, infectious disease with sepsis | King Abdul Aziz Specialist Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT06072222 Comparator | Jul 2020 → Dec 2021 | acute respiratory distress syndrome, infectious disease with sepsis | King Abdul Aziz Specialist Hospital | Completed | No outcome recorded |
| Phase 2 | NCT07512596 Background | Jul 2026 → Jul 2027 expected | bacterial pneumonia | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07318584 Comparator | Mar 2026 → Feb 2028 expected | escherichia coli discitis | Oregon Health and Science University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06841731 Comparator | Apr 2025 → Sep 2026 overdue | bacterial pneumonia | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05105035 Background | Jun 2022 → Oct 2023 | melioidosis | Arrevus Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04983901 Comparator | Sep 2021 → Oct 2023 | cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03485950 Comparator | May 2018 → May 2021 | infectious disease | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03230838 Comparator | Apr 2018 → Dec 2020 | pyelonephritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT03217136 Comparator | Apr 2018 → Mar 2020 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT02732327 Comparator | May → Jun 2016 | neoplasm, neutropenia | Forest Laboratories | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02475733 Comparator | Aug 2015 → Jun 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT02168816 Comparator | Mar 2014 → Feb 2017 | osteomyelitis | Loyola University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01381562 Comparator | Oct 2011 → Mar 2012 | intestinal infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT01147640 Comparator | Jun 2010 → Feb 2011 | — | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00752219 Comparator | Mar → Nov 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT05293132 Background | Feb 2022 → Jun 2023 | infectious disease with sepsis | Ain Shams University | Completed | Met primary |
| Phase 2/3 | NCT04879030 Background | Jan → Aug 2020 | chronic obstructive pulmonary disease | Haiphong University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2/3 | NCT03717350 Comparator | Oct 2018 → Jul 2021 | infectious disease with sepsis | Hellenic Institute for the Study of Sepsis | Unknown | No outcome recorded |
| Phase 2/3 | NCT04030741 Comparator | Sep 2018 → Dec 2019 | appendicitis | King Edward Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT03622450 Comparator | Jan 2016 → Jan 2018 | — | Nourhan Hassan Osama Thuraya Mohamed | Completed | No outcome recorded |
| Phase 2/3 | NCT02191475 Comparator | May 2014 → May 2017 | digestive system infectious disorder | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT07813767 Comparator | Oct 2026 → Sep 2028 expected | infectious disease with sepsis | Hellenic Institute for the Study of Sepsis | Recruiting | No outcome recorded |
| Phase 3 | NCT07326540 Background | Mar 2026 → Dec 2027 expected | Acinetobacter infectious disease, bacterial pneumonia | BioVersys SAS | Recruiting | No outcome recorded |
| Phase 3 | NCT06168734 Comparator | Jun 2025 → Jun 2027 | bacterial pneumonia | Venatorx Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT06847126 Comparator | Feb 2025 → Jun 2026 overdue | liver abscess (disease) | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| Phase 3 | NCT03630081 Comparator | Jan 2024 → Jan 2026 | acute pyelonephritis | Wockhardt | Unknown | No outcome recorded |
| Phase 3 | NCT05204368 Comparator | Mar 2023 → Jun 2025 | acute pyelonephritis | Evopoint Biosciences Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT05565222 Comparator | Mar 2023 → Apr 2026 | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 3 | NCT04979806 Comparator | Aug 2022 → Nov 2024 | acute pyelonephritis | Wockhardt | Completed | Met primary |
| Phase 3 | NCT04238390 Comparator | Jan 2022 → Jun 2024 | gram-negative bacterial infections | The University of Queensland | Withdrawn | No outcome recorded |
| Phase 3 | NCT04478721 Comparator | Dec 2020 → Dec 2024 | bacterial infectious disease | Andalusian Public Foundation for Health Research in Seville | Completed | Met primary |
| Phase 3 | NCT03840148 Comparator | Aug 2019 → Dec 2021 | acute pyelonephritis | Venatorx Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 3 | NCT03830333 Comparator | Mar 2019 → Oct 2020 | — | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT03543436 Comparator | Jan 2019 → Oct 2020 | bacterial urinary tract infection | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT03582007 Comparator | Oct 2018 → Jul 2019 | pneumonia | Polyphor Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03329092 Comparator | Apr 2018 → Feb 2023 | nosocomial infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03409679 Comparator | Mar 2018 → Jul 2019 | pneumonia | Polyphor Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03032380 Comparator | Oct 2017 → Feb 2019 | lung disorder | Shionogi | Completed | Met primary |
| Phase 3 | NCT02784704 Comparator | Oct 2016 → May 2017 | appendicitis | Tetraphase Pharmaceuticals, Inc | Completed | Met primary |
| Phase 3 | NCT02795949 Comparator | Oct 2016 → Jan 2020 | bacterial infectious disease | Andalusian Public Foundation for Health Research in Seville | Completed | Met primary |
| Phase 3 | NCT02820987 Comparator | Sep 2016 → Oct 2018 | infectious disease with sepsis | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 3 | NCT02486627 Comparator | Jan → Sep 2016 | acute pyelonephritis | Achaogen, Inc. | Completed | Met primary |
| Phase 3 | NCT02070757 Comparator | Sep 2014 → May 2018 | lung disorder, nosocomial infection | Merck & Co., Inc. | Completed | Met primary |
| Phase 3 | NCT02142751 Comparator | Jul 2014 → Dec 2018 | escherichia coli infection | Andalusian Public Foundation for Health Research in Seville | Completed | Missed primary |
| Phase 3 | NCT03477422 Comparator | Jan 2014 → May 2017 | acute pyelonephritis | Venus Remedies Limited | Completed | Met primary |
| Phase 3 | NCT02503761 Comparator | Aug 2013 → Jun 2015 | neonatal sepsis | Mansoura University | Completed | No outcome recorded |
| Phase 3 | NCT01808092 Comparator | Apr 2013 → Jan 2016 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT01726023 Comparator | Jan 2013 → Mar 2015 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT01597973 Comparator | Oct 2012 → Aug 2020 | bacterial infectious disease, pneumonia | University of Michigan | Completed | No outcome recorded |
| Phase 3 | NCT01292031 Comparator | May 2012 → Dec 2015 | bacterial pneumonia | Andalusian Public Foundation for Health Research in Seville | Completed | Missed primary |
| Phase 3 | NCT01499290 Comparator | Mar 2012 → Apr 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01445678 Comparator | Dec 2011 → Oct 2013 | — | Merck & Co., Inc. | Completed | Met primary |
| Phase 3 | NCT00771316 Comparator | Dec 2008 → Jun 2009 | urinary tract infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00534287 Comparator | Oct 2007 → Apr 2010 | infectious disease with sepsis | Competence Network Sepsis | Completed | No outcome recorded |
| Phase 4 | NCT07556107 Comparator | Jun 2026 → Jun 2028 expected | acute kidney injury, infectious disease with sepsis | Bassett Healthcare | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07590648 Background | Jun 2026 → Jul 2028 expected | bacterial infectious disease, childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm, neutropenia | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07694700 Comparator | Dec 2025 → Aug 2026 overdue | primary bacterial infectious disease | Beni-Suef University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07236944 Comparator | Dec 2025 → Mar 2029 expected | bacterial urinary tract infection | Uppsala University | Recruiting | No outcome recorded |
| Phase 4 | NCT07314281 Comparator | Apr 2025 → Jan 2027 expected | typhoid fever | Indus Hospital and Health Network | Recruiting | No outcome recorded |
| Phase 4 | NCT07004049 Comparator | Apr 2025 → Dec 2028 expected | bacterial pneumonia, infectious disease with sepsis | National University of Singapore | Recruiting | No outcome recorded |
| Phase 4 | NCT06342115 Comparator | Mar 2025 → Aug 2027 expected | neutropenia | Beneficência Portuguesa de São Paulo | Recruiting | No outcome recorded |
| Phase 4 | NCT05922124 Comparator | Sep 2024 → Jul 2026 overdue | Acinetobacter infectious disease | Rambam Health Care Campus | Recruiting | No outcome recorded |
| Phase 4 | NCT05784844 Comparator | Aug 2024 → Apr 2025 | neutropenia | Wake Forest University Health Sciences | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT05977868 Comparator | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT05355350 Comparator | Jul 2022 → Jul 2025 | bacterial infectious disease | Rambam Health Care Campus | Withdrawn | No outcome recorded |
| Phase 4 | NCT05102162 Comparator | Dec 2021 → Feb 2023 | pneumonia | University of Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04882085 Comparator | Aug 2021 → Aug 2023 | acute pyelonephritis, bacterial pneumonia, infectious peritonitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT04370145 Comparator | May → Oct 2021 | cholangitis | Tongji Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04489459 Comparator | Sep 2019 → Jul 2020 | — | Al-Azhar University | Unknown | No outcome recorded |
| Phase 4 | NCT03671967 Comparator | May 2019 → Jan 2027 expected | bacterial infectious disease | Rambam Health Care Campus | Recruiting | No outcome recorded |
| Phase 4 | NCT03891433 Comparator | Apr 2019 → Dec 2024 | Klebsiella pneumonia, bacterial urinary tract infection, escherichia coli infection | Universidad del Norte | Suspended | No outcome recorded |
| Phase 4 | NCT02894684 Background | Jan 2017 → Feb 2019 | Pseudomonas infection, cystic fibrosis | Liverpool Heart and Chest Hospital NHS Foundation Trust | Completed | Met primary |
| Phase 4 | NCT02437045 Comparator | Apr 2015 → Dec 2020 | bacterial infectious disease | The University of Queensland | Completed | Missed primary |
| Phase 4 | NCT02176122 Comparator | Feb 2014 → Jul 2017 | bacterial infectious disease | The University of Queensland | Terminated | Missed primary |
| Phase 4 | NCT02047773 Comparator | Jan 2014 → Feb 2020 | bronchiectasis | University of Edinburgh | Completed | No outcome recorded |
| Phase 4 | NCT01667094 Comparator | Sep 2012 → Jul 2017 | cystic fibrosis | The Alfred | Unknown | No outcome recorded |
| Phase 4 | NCT01297842 Comparator | May 2011 → Apr 2013 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT01044719 Comparator | Jan → Oct 2010 | cystic fibrosis | Imperial College London | Unknown | No outcome recorded |
| — | NCT06818565 Comparator | Feb 2025 → Dec 2026 expected | liver disorder | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT06080698 Comparator | Feb 2024 → May 2027 expected | gram-negative bacterial infections | Johns Hopkins University | Recruiting | No outcome recorded |
| — | NCT06051513 Background | Nov 2023 → Dec 2025 overdue | — | Southeast University, China | Recruiting | No outcome recorded |
| — | NCT05925309 Background | Jul 2023 → Dec 2027 expected | biliary atresia, cholangitis | Children's Hospital of Fudan University | Recruiting | No outcome recorded |
| — | NCT03884881 Background | Jan 2018 → Dec 2019 | pneumonia | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| — | NCT03344627 Comparator | Nov 2017 → Nov 2018 | infectious disease with sepsis, multiple organ dysfunction syndrome | Mahidol University | Completed | No outcome recorded |
| — | NCT03019965 Comparator | Feb 2017 → Dec 2019 | infectious disease with sepsis | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| — | NCT02788240 Background | May 2016 → Jul 2017 | liver failure | Institute of Liver and Biliary Sciences, India | Terminated | No outcome recorded |
| — | NCT01828892 Background | Mar 2014 → Jun 2017 | intestinal fistula | Jinling Hospital, China | Unknown | No outcome recorded |
| — | NCT00891423 Comparator | Apr 2009 → Jan 2010 | infectious disease with sepsis | Austin Health | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | Antabio | Results Antabio Highlights New Data on their Novel β‑lactam/β‑lactamase Inhibitor, Meropenem-Pilabactam (formerly Meropenem-ANT3310) at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases antabio.com ↗
Data from Phase 1 studies showed favorable safety and PK profiles in renally-impaired subjects and good lung penetration in healthy volunteers. |
| 2024-09-03 | Antabio | Results Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections antabio.com ↗
ANT3310 and meropenem demonstrated very compatible PK with no mutual PK interaction. |
| 2024-02-20 | Menarini Group | Results New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection menarini.com ↗
The results showed that cefepime-taniborbactam was superior to meropenem for the primary efficacy endpoint and had a similar safety profile to meropenem. |
| 2020-07-09 | Menarini Group | Results Menarini Ricerche Announces the Latest Findings of its Vaborem™ and Quofenix™ Clinical Studies menarini.com ↗
Menarini Ricerche, the R&D division of the Menarini Group, announces that it has published four abstracts presenting the latest findings related to its meropenem/vaborbactam (Vaborem ™ ) and delafloxacin (Quofenix ™ ) clinical studies, confirming Menarini’s commitment to fighting life-threatening bacterial infections. |
| 2020-05-06 | Antabio | Regulatory Antabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation for MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens antabio.com ↗
Antabio SAS announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to Antabio’s MEM-ANT3310, a combination of meropenem (MEM) and the novel broad-spectrum serine beta-lactamase inhibitor ANT3310. |
| 2019-06-21 | Antabio | Regulatory Antabio Receives QIDP Designation from the U.S. FDA for the Development of Its Metallo Beta-Lactamase inhibitor ANT2681 antabio.com ↗ |
| 2018-12-20 | Menarini Group | Regulatory The Menarini Group announces meropenem/vaborbactam European marketing authorization menarini.com ↗
Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections. |
| 2018-09-11 | Merck Sharp & Dohme LLC | Results Merck’s ZERBAXA® (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia merck.com ↗ |
| 2018-03-23 | Antabio | Results First publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor program antabio.com ↗
The paper describes the characterisation of a prototype compound which displays good potentiation of meropenem activity against CRE bacteria, in both in vitro and in vivo studies, combined with promising drug-like properties. |
| 2017-04-24 | Pfizer | Results Pivotal Phase III Study Underscores Efficacy Of Zavicefta™ (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals pfizer.com ↗
In addition, patients treated with Zavicefta and Meropenem experienced comparable rates of tolerability consistent with the known profile of ceftazidime alone. |
All press releases naming this drug 10 releases
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 177 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meropenem | “Beta lactam antibiotics for non-ESBL E. coli infections include preferred ceftriaxone or alternative cephalosporins (cefepime, ceftazidime), penicillins...” NCT07318584 ↗174“The study is designed to determine whether 3 days of antibiotic treatment with meropenem (with or without coverage for MRSA) can reduce the risk of colonization with...” NCT00410527 ↗ “The intravenous-group will receive Beta-lactam antimicrobials (i.e Piperacillin-Tazobactum 4.5g q 8 hourly or Ceftriaxone 1g q 12 hourly or Meropenem 1g q 8 hourly or...” NCT06847126 ↗ “This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin,...” NCT02168816 ↗ “The beta-lactam antibiotics with activity against gram-negative bacilli in this study included piperacillin-tazobactam, ticarcillin-clavulanate, imipenem-cilastin, meropenem,...” NCT04879030 ↗ “Antibiotics: Ceftazidime-Avibactam or Combination antibiotics (eg. Meropenem-Colistin, Imipenem-Colistin, Tigecycline-Amikacin, Tigecycline-Gentamicin, Tigecycline-Meropenem or...” NCT05862402 ↗ “Drug stop within 24 hours after randomization:Piperacillin-tazobactam, amikacin, meropenem, cefepime, ceftazidime, vancomycin, teicoplanin, ciprofloxacin, levofloxacine and...” NCT07590648 ↗ “Children in non-operative treatment group will be given intravenous meropenem (10 mg/kg/dose x IV x TDS) and metronidazole (20 mg/kg/day divided into 3 doses) for at least 48 hours.” NCT04030741 ↗ “main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem” NCT04882085 ↗ “flucloxacillin, meropenem, and piperacillin/clavulanic acid) in critically ill patients with septic shock.” PMID 40119275 ↗ Mar 2025 “Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin” NCT03409679 ↗ |
| Known as | ICI 194,660 | ChEMBL registry synonym — accepted as the source's own label CHEMBL127 ↗ |
| Known as | Mepin | “1.0g meropenem for injection (Mepin)” NCT05340530 ↗ |
| Known as | MEPM | “Patients in the mild cholangitis group were randomized to receive cefoperazone sodium tazobactam sodium (CSTS) or meropenem (MEPM).” PMID 37678274 ↗ Dec 2023 |
| Known as | Meronem | ChEMBL registry synonym — accepted as the source's own label CHEMBL127 ↗ |
| Known as | Meronem (meropenem) | “Meronem® (meropenem)” NCT00534287 ↗ |
| Known as | Meropenem "Hospira" | “meropenem 500 mg (Meropenem "Hospira"), powder for concentrate” NCT03157388 ↗ |
| Known as | Meropenem (as trihydrate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL127 ↗ |
| Known as | Meropenem anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL127 ↗ |
| Known as | Meropenem component of vabomere | ChEMBL registry synonym — accepted as the source's own label CHEMBL127 ↗ |
| Known as | Meropenem for injection | “Meropenem for injection is a β-lactam.” NCT07512596 ↗ |
| Known as | Meropenem hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL127 ↗ |
| Known as | Meropenem Injection | “Drug: Meropenem Injection” NCT04370145 ↗ |
| Known as | Meropenem trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL127 ↗ |
| Known as | Merrem | ChEMBL registry synonym — accepted as the source's own label CHEMBL127 ↗ |
| Known as | MERREM I.V. | “This study is being carried out to see whether the antibiotic 'Meropenem' (which is also known as MERREM I.V.) provides protection from developing a pancreatic infection.” NCT00061438 ↗1“high dose antibiotic (meropenem, MERREM® I.V.)” NCT00050401 ↗ |
| Known as | Merrem(R) | “Meropenem or Merrem(R)” NCT01158937 ↗ |
| Known as | MPM | “meropenem (MPM): 30 mg/kg or 40 mg/kg for meningitis q8h (max. 2 g q8h)” NCT07484633 ↗ |
| Known as | NSC-759621 | ChEMBL registry synonym — accepted as the source's own label CHEMBL127 ↗ |
| Known as | SM-7338 | ChEMBL registry synonym — accepted as the source's own label CHEMBL127 ↗ |
| Modality | Small molecule | “Meropenem is a beta-lactam type antibiotic with time-dependent bactericidal activity” NCT01158937 ↗ |
| Route | Intravenous | “MERREM I.V. 2g as a 3 hour infusion every 8 hours” NCT00050401 ↗ |